2026 Q2 -tulosraportti
42 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 164 | - | - | ||
| 123 | - | - | ||
| 79 | - | - | ||
| 131 | - | - | ||
| 250 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sitten · MuokattuI think Photocure is an exciting Norwegian healthcare case where much of the upside lies in further growth for Hexvix/Cysview in bladder cancer diagnostics. Price target is 75kr-85kr from 3 analysts: • Strong position in bladder cancer • USA is clearly the most important growth engine • High gross margin and good scalability as volumes increase • Increasing installed base of blue-light equipment provides potential for more recurring sales • Already commercialized product – not a typical binary biotech-case • Significant potential if the use of blue-light cystoscopy continues to increase Photocure therefore doesn't need to "reinvent" the case. The product is on the market, revenues are growing, and increased use can provide strong operational gearing. If the USA development continues, I believe earnings can grow significantly faster than revenue – and then the stock can become interestingly priced.
In that case, the willingness to pay for royalties should be better than what the Chinese showed for milestones.
·2.9.The cat is out of the bag, Citadel holds several days' turnover short in PHO. A squeeze could quickly happen here. And this is just one of probably several short sellers wreaking havoc.
Is the cause of significantly increased interest and price driving based on known information and already arrived news. Obviously, we are unnaturally low these days. I am overweight here myself, and incidentally, the price may gladly be kept low by short sellers so I can buy more. =]- ·1.9.So the short-seller swine was suddenly visible.
One of the short-seller pigs, you mean, I suppose. Gods know how many operate under 0.5%🤬 
·31.8.FDA changed the wording in the label for approved use of Cysview in June this year. Before it said: "Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system… Now: “Use CYSVIEW with the KARL STORZ D-Light C … System or other FDA-authorized imaging device intended to perform blue light cystoscopy … with hexaminolevulinate hydrochloride… So, Cysview can be used by any scope approved for BLC! For me, this emphasizes that FDA wants to get more manufacturers into BLC and that they are paving the way, regardless of whether it's via 510(k) after reclassification or not. Becoming more positive about a quick final order as well. Anyway, one barrier has been overcome now; Cysview is no longer only approved with KS-scopes. Cysview can now be used by all scopes approved for BLC, which currently only includes KS, but then it's just a matter of getting the scopes approved. Get the reclassification going!📈NM in nitpicking on a Monday morning? You are of course right👍 I'm the one who's becoming positive, yes. If you read the entire paragraph as a whole, not sentence by sentence, it might become more obvious that I'm speaking from my own perspective. Have a nice day😊- ·31.8.With upcoming royalties from Asieris and a halving of royalty payments to Ibsen for europa, PHO can quickly surpass medistim in both revenue and EBIT. Medistim is currently priced 3x of PHO.Photocure pivots like a book publisher? "Peer Gynt and A Doll's House - soon at your nearest uro-oncological department". All the pages in the books are blue and the text is pink.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
42 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sitten · MuokattuI think Photocure is an exciting Norwegian healthcare case where much of the upside lies in further growth for Hexvix/Cysview in bladder cancer diagnostics. Price target is 75kr-85kr from 3 analysts: • Strong position in bladder cancer • USA is clearly the most important growth engine • High gross margin and good scalability as volumes increase • Increasing installed base of blue-light equipment provides potential for more recurring sales • Already commercialized product – not a typical binary biotech-case • Significant potential if the use of blue-light cystoscopy continues to increase Photocure therefore doesn't need to "reinvent" the case. The product is on the market, revenues are growing, and increased use can provide strong operational gearing. If the USA development continues, I believe earnings can grow significantly faster than revenue – and then the stock can become interestingly priced.In that case, the willingness to pay for royalties should be better than what the Chinese showed for milestones.
- ·2.9.The cat is out of the bag, Citadel holds several days' turnover short in PHO. A squeeze could quickly happen here. And this is just one of probably several short sellers wreaking havoc.Is the cause of significantly increased interest and price driving based on known information and already arrived news. Obviously, we are unnaturally low these days. I am overweight here myself, and incidentally, the price may gladly be kept low by short sellers so I can buy more. =]
- ·1.9.So the short-seller swine was suddenly visible.One of the short-seller pigs, you mean, I suppose. Gods know how many operate under 0.5%🤬
- ·31.8.FDA changed the wording in the label for approved use of Cysview in June this year. Before it said: "Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system… Now: “Use CYSVIEW with the KARL STORZ D-Light C … System or other FDA-authorized imaging device intended to perform blue light cystoscopy … with hexaminolevulinate hydrochloride… So, Cysview can be used by any scope approved for BLC! For me, this emphasizes that FDA wants to get more manufacturers into BLC and that they are paving the way, regardless of whether it's via 510(k) after reclassification or not. Becoming more positive about a quick final order as well. Anyway, one barrier has been overcome now; Cysview is no longer only approved with KS-scopes. Cysview can now be used by all scopes approved for BLC, which currently only includes KS, but then it's just a matter of getting the scopes approved. Get the reclassification going!📈NM in nitpicking on a Monday morning? You are of course right👍 I'm the one who's becoming positive, yes. If you read the entire paragraph as a whole, not sentence by sentence, it might become more obvious that I'm speaking from my own perspective. Have a nice day😊
- ·31.8.With upcoming royalties from Asieris and a halving of royalty payments to Ibsen for europa, PHO can quickly surpass medistim in both revenue and EBIT. Medistim is currently priced 3x of PHO.Photocure pivots like a book publisher? "Peer Gynt and A Doll's House - soon at your nearest uro-oncological department". All the pages in the books are blue and the text is pink.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 164 | - | - | ||
| 123 | - | - | ||
| 79 | - | - | ||
| 131 | - | - | ||
| 250 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
42 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sitten · MuokattuI think Photocure is an exciting Norwegian healthcare case where much of the upside lies in further growth for Hexvix/Cysview in bladder cancer diagnostics. Price target is 75kr-85kr from 3 analysts: • Strong position in bladder cancer • USA is clearly the most important growth engine • High gross margin and good scalability as volumes increase • Increasing installed base of blue-light equipment provides potential for more recurring sales • Already commercialized product – not a typical binary biotech-case • Significant potential if the use of blue-light cystoscopy continues to increase Photocure therefore doesn't need to "reinvent" the case. The product is on the market, revenues are growing, and increased use can provide strong operational gearing. If the USA development continues, I believe earnings can grow significantly faster than revenue – and then the stock can become interestingly priced.In that case, the willingness to pay for royalties should be better than what the Chinese showed for milestones.
- ·2.9.The cat is out of the bag, Citadel holds several days' turnover short in PHO. A squeeze could quickly happen here. And this is just one of probably several short sellers wreaking havoc.Is the cause of significantly increased interest and price driving based on known information and already arrived news. Obviously, we are unnaturally low these days. I am overweight here myself, and incidentally, the price may gladly be kept low by short sellers so I can buy more. =]
- ·1.9.So the short-seller swine was suddenly visible.One of the short-seller pigs, you mean, I suppose. Gods know how many operate under 0.5%🤬
- ·31.8.FDA changed the wording in the label for approved use of Cysview in June this year. Before it said: "Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system… Now: “Use CYSVIEW with the KARL STORZ D-Light C … System or other FDA-authorized imaging device intended to perform blue light cystoscopy … with hexaminolevulinate hydrochloride… So, Cysview can be used by any scope approved for BLC! For me, this emphasizes that FDA wants to get more manufacturers into BLC and that they are paving the way, regardless of whether it's via 510(k) after reclassification or not. Becoming more positive about a quick final order as well. Anyway, one barrier has been overcome now; Cysview is no longer only approved with KS-scopes. Cysview can now be used by all scopes approved for BLC, which currently only includes KS, but then it's just a matter of getting the scopes approved. Get the reclassification going!📈NM in nitpicking on a Monday morning? You are of course right👍 I'm the one who's becoming positive, yes. If you read the entire paragraph as a whole, not sentence by sentence, it might become more obvious that I'm speaking from my own perspective. Have a nice day😊
- ·31.8.With upcoming royalties from Asieris and a halving of royalty payments to Ibsen for europa, PHO can quickly surpass medistim in both revenue and EBIT. Medistim is currently priced 3x of PHO.Photocure pivots like a book publisher? "Peer Gynt and A Doll's House - soon at your nearest uro-oncological department". All the pages in the books are blue and the text is pink.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 164 | - | - | ||
| 123 | - | - | ||
| 79 | - | - | ||
| 131 | - | - | ||
| 250 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt